Literature DB >> 25986402

Progression of behavioural despair in R6/2 and Hdh knock-in mouse models recapitulates depression in Huntington's disease.

Alessandro Ciamei1, Peter J Detloff2, A Jennifer Morton3.   

Abstract

In Huntington's disease (HD) depression is observed before the disease is diagnosed, and is likely to be a component of the disease, rather than a consequence. Depression in HD patients does not progress in parallel with other symptoms; rather it peaks at early- to mid-stages of the disease and declines thereafter. In mice, depressive-like behaviours can be measured as an increase in behavioural despair (floating) observed in the forced swim test (FST). Floating in the FST is modulated differently by antidepressants with different mechanisms of action. Drugs that increase levels of serotonin inhibit floating by promoting horizontal swimming, whereas drugs that increase levels of noradrenaline inhibit floating by enhancing vertical swimming (climbing). We compared the FST behavioural profiles of two different allelic series of HD mice, a fragment model (R6/2 mice carrying 120, 250, or 350 CAG repeats), and a knock-in model (Hdh mice carrying 50, 150, or 250 CAG repeats). The FST behavioural profile was similar in both lines. It was characterized by an early-stage increase in floating, and then, as the mice aged, floating decreased, whereas active behaviours of swimming and climbing increased. Our results show that, as with depression in HD patients, floating in HD mice does not progress linearly, suggesting that, at the late stages of the disease, an increase in serotonergic and noradrenergic activity might contribute to lower floating levels in HD mice. If similar compensatory changes occur in humans, this should be taken into account when considering the treatment of depression in HD patients.
Copyright © 2015 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Depression; Forced swim test; Huntington's disease; Noradrenaline; Serotonin

Mesh:

Year:  2015        PMID: 25986402     DOI: 10.1016/j.bbr.2015.05.010

Source DB:  PubMed          Journal:  Behav Brain Res        ISSN: 0166-4328            Impact factor:   3.332


  8 in total

Review 1.  Progress in developing transgenic monkey model for Huntington's disease.

Authors:  Brooke R Snyder; Anthony W S Chan
Journal:  J Neural Transm (Vienna)       Date:  2017-11-10       Impact factor: 3.575

2.  Sex-dependent behavioral impairments in the HdhQ350/+ mouse line.

Authors:  Jessica K Cao; Peter J Detloff; Richard G Gardner; Nephi Stella
Journal:  Behav Brain Res       Date:  2017-09-18       Impact factor: 3.332

3.  PIAS1 Regulates Mutant Huntingtin Accumulation and Huntington's Disease-Associated Phenotypes In Vivo.

Authors:  Joseph Ochaba; Alex Mas Monteys; Jacqueline G O'Rourke; Jack C Reidling; Joan S Steffan; Beverly L Davidson; Leslie M Thompson
Journal:  Neuron       Date:  2016-04-14       Impact factor: 17.173

4.  Chronic Paroxetine Treatment Prevents the Emergence of Abnormal Electroencephalogram Oscillations in Huntington's Disease Mice.

Authors:  Sandor Kantor; Janos Varga; Shreya Kulkarni; A Jennifer Morton
Journal:  Neurotherapeutics       Date:  2017-10       Impact factor: 7.620

Review 5.  What is the Pathogenic CAG Expansion Length in Huntington's Disease?

Authors:  Jasmine Donaldson; Sophie Powell; Nadia Rickards; Peter Holmans; Lesley Jones
Journal:  J Huntingtons Dis       Date:  2021

6.  Distinct histological alterations of cortical interneuron types in mouse models of Huntington's disease.

Authors:  Kerstin Voelkl; Elena Katharina Schulz-Trieglaff; Rüdiger Klein; Irina Dudanova
Journal:  Front Neurosci       Date:  2022-09-26       Impact factor: 5.152

7.  Impaired Nitric Oxide Mediated Vasodilation In The Peripheral Circulation In The R6/2 Mouse Model Of Huntington's Disease.

Authors:  Andrew D Kane; Youguo Niu; Emilio A Herrera; A Jennifer Morton; Dino A Giussani
Journal:  Sci Rep       Date:  2016-05-16       Impact factor: 4.379

8.  Disease-modifying effects of ganglioside GM1 in Huntington's disease models.

Authors:  Melanie Alpaugh; Danny Galleguillos; Juan Forero; Luis Carlos Morales; Sebastian W Lackey; Preeti Kar; Alba Di Pardo; Andrew Holt; Bradley J Kerr; Kathryn G Todd; Glen B Baker; Karim Fouad; Simonetta Sipione
Journal:  EMBO Mol Med       Date:  2017-11       Impact factor: 12.137

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.